Skip to main content
Erschienen in: Journal of Neuro-Oncology 3/2023

14.09.2023 | Research

Relationship between apparent diffusion coefficient and survival as a function of distance from gross tumor volume on radiation planning MRI in newly diagnosed glioblastoma

verfasst von: Pejman Jabehdar Maralani, James Stewart, Shivaprakash Hiremath, Liam Lawrence, Rachel Chan, Angus Lau, Hanbo Chen, Aimee Chan, Liang K. Zeng, Chia-Lin Tseng, Sten Myrehaug, Hany Soliman, Jay Detsky, Chinthaka Heyn, MaryJane Lim Fat, Nir Lipsman, Arjun Sahgal

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the changes in apparent diffusion coefficient (ADC) within incrementally-increased margins beyond the gross tumor volume (GTV) on post-operative radiation planning MRI and their prognostic utility in glioblastoma.

Methods

Radiation planning MRIs of adult patients with newly diagnosed glioblastoma from 2017 to 2020 were assessed. The ADC values were normalized to contralateral normal white matter (nADC). Using 1 mm isotropic incremental margin increases from the GTV, the nADC values were calculated at each increment. Age, ECOG performance status, extent of resection and MGMT promoter methylation status were obtained from medical records. Using univariate and multivariable Cox regression analysis, association of nADC to progression-free and overall survival (PFS, OS) was assessed at each increment.

Results

Seventy consecutive patients with mean age of 53.6 ± 10.3 years, were evaluated. The MGMT promoter was methylated in 31 (44.3%), unmethylated in 36 (51.6%) and unknown in 3 (4.3%) patients. 11 (16%) underwent biopsy, 41 (44%) subtotal resection and 18 (26%) gross total resection. For each 1 mm increase in distance from GTV, the nADC decreased by 0.16% (p < 0.0001). At 1–5 mm increment, the nADC was associated with OS (p < 0.01). From 6 to 11 mm increment the nADC was associated with OS with the p-value gradually increasing from 0.018 to 0.046. nADC was not associated with PFS.

Conclusion

The nADC values at 1–11 mm increments from the GTV margin were associated with OS. Future prospective multicenter studies are needed to validate the findings and to pave the way for the utilization of ADC for margin reduction in radiation planning.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous System: a summary. Neurooncology 23:1231–1251. https://doi.org/10.1093/neuonc/noab106CrossRef Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous System: a summary. Neurooncology 23:1231–1251. https://​doi.​org/​10.​1093/​neuonc/​noab106CrossRef
12.
Zurück zum Zitat Pollom EL, Fujimoto D, Wynne J, Seiger K, Modlin LA, Jacobs LR, Azoulay M, von Eyben R, Tupper L, Gibbs IC, Hancock SL, Li G, Chang SD, Adler JR, Harsh GR, Harraher C, Nagpal S, Thomas RP, Recht LD, Choi CYH, Soltys SG (2017) Phase 1/2 trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent and adjuvant temozolomide in newly diagnosed supratentorial glioblastoma: health-related quality of life results. Int J Radiat Oncol Biol Phys 98:123–130. https://doi.org/10.1016/j.ijrobp.2017.01.242CrossRefPubMedPubMedCentral Pollom EL, Fujimoto D, Wynne J, Seiger K, Modlin LA, Jacobs LR, Azoulay M, von Eyben R, Tupper L, Gibbs IC, Hancock SL, Li G, Chang SD, Adler JR, Harsh GR, Harraher C, Nagpal S, Thomas RP, Recht LD, Choi CYH, Soltys SG (2017) Phase 1/2 trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent and adjuvant temozolomide in newly diagnosed supratentorial glioblastoma: health-related quality of life results. Int J Radiat Oncol Biol Phys 98:123–130. https://​doi.​org/​10.​1016/​j.​ijrobp.​2017.​01.​242CrossRefPubMedPubMedCentral
14.
15.
Zurück zum Zitat Wen Q, Jalilian L, Lupo JM, Molinaro AM, Chang SM, Clarke J, Prados M, Nelson SJ (2015) Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. J Neurooncol 121:331–339. https://doi.org/10.1007/s11060-014-1636-6CrossRefPubMed Wen Q, Jalilian L, Lupo JM, Molinaro AM, Chang SM, Clarke J, Prados M, Nelson SJ (2015) Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. J Neurooncol 121:331–339. https://​doi.​org/​10.​1007/​s11060-014-1636-6CrossRefPubMed
18.
Zurück zum Zitat Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Al Yung WK, Cloughesy TF, Wen PY, Gilbert MR, Committee tJBTDDCISS, Whitney A, Sandak D, Musella A, Haynes C, Wallace M, Arons DF, Kingston A, Sul J, Krainak D, tJBTDDCISS Committee (2015) Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neurooncology 17:1188–1198. https://doi.org/10.1093/neuonc/nov095CrossRef Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Al Yung WK, Cloughesy TF, Wen PY, Gilbert MR, Committee tJBTDDCISS, Whitney A, Sandak D, Musella A, Haynes C, Wallace M, Arons DF, Kingston A, Sul J, Krainak D, tJBTDDCISS Committee (2015) Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neurooncology 17:1188–1198. https://​doi.​org/​10.​1093/​neuonc/​nov095CrossRef
19.
Zurück zum Zitat Jabehdar Maralani P, Myrehaug S, Mehrabian H, Chan AKM, Wintermark M, Heyn C, Conklin J, Ellingson BM, Rahimi S, Lau AZ, Tseng CL, Soliman H, Detsky J, Daghighi S, Keith J, Munoz DG, Das S, Atenafu EG, Lipsman N, Perry J, Stanisz G, Sahgal A (2021) Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma. Radiother Oncol 156:258–265. https://doi.org/10.1016/j.radonc.2020.12.037CrossRefPubMed Jabehdar Maralani P, Myrehaug S, Mehrabian H, Chan AKM, Wintermark M, Heyn C, Conklin J, Ellingson BM, Rahimi S, Lau AZ, Tseng CL, Soliman H, Detsky J, Daghighi S, Keith J, Munoz DG, Das S, Atenafu EG, Lipsman N, Perry J, Stanisz G, Sahgal A (2021) Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma. Radiother Oncol 156:258–265. https://​doi.​org/​10.​1016/​j.​radonc.​2020.​12.​037CrossRefPubMed
20.
Zurück zum Zitat Stewart J, Sahgal A, Lee Y, Soliman H, Tseng CL, Detsky J, Husain Z, Ho L, Das S, Maralani PJ, Lipsman N, Stanisz G, Perry J, Chen H, Atenafu EG, Campbell M, Lau AZ, Ruschin M, Myrehaug S (2021) Quantitating Interfraction target dynamics during concurrent chemoradiation for glioblastoma: a prospective serial imaging study. Int J Radiat Oncol Biol Phys 109:736–746. https://doi.org/10.1016/j.ijrobp.2020.10.002CrossRefPubMed Stewart J, Sahgal A, Lee Y, Soliman H, Tseng CL, Detsky J, Husain Z, Ho L, Das S, Maralani PJ, Lipsman N, Stanisz G, Perry J, Chen H, Atenafu EG, Campbell M, Lau AZ, Ruschin M, Myrehaug S (2021) Quantitating Interfraction target dynamics during concurrent chemoradiation for glioblastoma: a prospective serial imaging study. Int J Radiat Oncol Biol Phys 109:736–746. https://​doi.​org/​10.​1016/​j.​ijrobp.​2020.​10.​002CrossRefPubMed
23.
Zurück zum Zitat Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. https://doi.org/10.1200/jco.2009.26.3541CrossRefPubMed Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. https://​doi.​org/​10.​1200/​jco.​2009.​26.​3541CrossRefPubMed
28.
Zurück zum Zitat Vivas-Buitrago T, Domingo RA, Tripathi S, De Biase G, Brown D, Akinduro OO, Ramos-Fresnedo A, Sabsevitz DS, Bendok BR, Sherman W, Parney IF, Jentoft ME, Middlebrooks EH, Meyer FB, Chaichana KL, Quinones-Hinojosa A (2022) Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma. J Neurosurg 136:1–8. https://doi.org/10.3171/2020.10.Jns203366CrossRefPubMed Vivas-Buitrago T, Domingo RA, Tripathi S, De Biase G, Brown D, Akinduro OO, Ramos-Fresnedo A, Sabsevitz DS, Bendok BR, Sherman W, Parney IF, Jentoft ME, Middlebrooks EH, Meyer FB, Chaichana KL, Quinones-Hinojosa A (2022) Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma. J Neurosurg 136:1–8. https://​doi.​org/​10.​3171/​2020.​10.​Jns203366CrossRefPubMed
29.
Zurück zum Zitat Kim MM, Sun Y, Aryal MP, Parmar HA, Piert M, Rosen B, Mayo CS, Balter JM, Schipper M, Gabel N, Briceño EM, You D, Heth J, Al-Holou W, Umemura Y, Leung D, Junck L, Wahl DR, Lawrence TS, Cao Y (2021) A phase 2 study of dose-intensified Chemoradiation using biologically based Target volume definition in patients with newly diagnosed Glioblastoma. Int J Radiat Oncol Biol Phys 110:792–803. https://doi.org/10.1016/j.ijrobp.2021.01.033CrossRefPubMedPubMedCentral Kim MM, Sun Y, Aryal MP, Parmar HA, Piert M, Rosen B, Mayo CS, Balter JM, Schipper M, Gabel N, Briceño EM, You D, Heth J, Al-Holou W, Umemura Y, Leung D, Junck L, Wahl DR, Lawrence TS, Cao Y (2021) A phase 2 study of dose-intensified Chemoradiation using biologically based Target volume definition in patients with newly diagnosed Glioblastoma. Int J Radiat Oncol Biol Phys 110:792–803. https://​doi.​org/​10.​1016/​j.​ijrobp.​2021.​01.​033CrossRefPubMedPubMedCentral
Metadaten
Titel
Relationship between apparent diffusion coefficient and survival as a function of distance from gross tumor volume on radiation planning MRI in newly diagnosed glioblastoma
verfasst von
Pejman Jabehdar Maralani
James Stewart
Shivaprakash Hiremath
Liam Lawrence
Rachel Chan
Angus Lau
Hanbo Chen
Aimee Chan
Liang K. Zeng
Chia-Lin Tseng
Sten Myrehaug
Hany Soliman
Jay Detsky
Chinthaka Heyn
MaryJane Lim Fat
Nir Lipsman
Arjun Sahgal
Publikationsdatum
14.09.2023
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2023
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-023-04440-1

Weitere Artikel der Ausgabe 3/2023

Journal of Neuro-Oncology 3/2023 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.